

IN THE SPECIFICATION:

Please amend paragraph [0065] as follows:

FIG. 29[[A]] illustrates the molecular structure of acidic drugs, ibuprofen, and naproxen;

Please amend paragraph [0066] as follows:

~~FIG. 29B illustrates molecular structure of neuropeptides, angiotensin II, and neurotensin;~~

Please amend paragraph [0162] as follows:

Polyclonal antibodies raised against commercially available ibuprofen, naproxen, angiotensin II, and neurotensin (~~Figures 29A and 29B~~), coupled covalently to Blue Carrier immunogenic protein, were raised in rabbits using a method similar to those described elsewhere [3,4]. The molecular structure of ibuprofen and naproxen are illustrated in Figure 29.

Angiotensin II and neurotensin are peptide sequences well known to one of skill in the art. The purification of the antibodies from rabbit antisera was performed by HPLC using r-Protein A affinity chromatography as previously described [4]. Conjugates for immunization were prepared by various methods with the same modifications [1,5-7]. The method described by Grafe and Hoffmann [5] was used to link ibuprofen to the Blue Carrier immunogenic protein. The method described by Shi *et al.* [6] was used to link naproxen to the immunogenic protein. The linking of the peptides to the immunogenic protein was performed as previously reported for other carriers [1,7].

REMARKS:

Applicants have amended FIGs. 33A, 33B and 33C; and, have deleted FIG. 29B. Replacement Sheets have been submitted herewith. The amendments to the figures were made to represent known peptide sequences by name only in order to obviate the Notice to Comply requirements that were mailed on August 13, 2004. The known peptide sequences were removed by deleting FIG. 29B in its entirety, and amending FIGs. 33A, 33B and 33C to delete peptide sequences that were originally illustrated. Accordingly, the representations of the known amino acid sequences provided in FIGs. 29B, 33a, 33b and 33c are not essential material and do not require formal sequence listings. *See* MPEP § 2422.03. The specification has been amended to reflect the amendments to the figures.

No new matter has been added by the present amendment. Applicants submit that claims 1-321 satisfy all of the criteria for patentability and remain in condition for allowance. Examination and allowance of the application is hereby respectfully solicited.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1853. Should such additional fees be associated with an extension of time, Applicants respectfully request that this paper be considered a petition therefor.

Respectfully submitted,

Date: October 12, 2004


Brian S. Boyer, Reg. No. 52,643
Attorney for Applicants

Squire, Sanders & Dempsey, LLP
One Maritime Plaza, Suite 300
San Francisco, CA 94111-3492
Telephone: (415) 954-0230
Facsimile: (415) 393-9887